OCUL - Ocular Therapeutix Inc logo

OCUL

Ocular Therapeutix Inc

Ocular Therapeutix develops ophthalmic therapies using bioresorbable hydrogel technology. Its products include DEXTENZA for post-surgical ocular inflammation and AXPAXLI, in phase 3 for wet age-related macular degeneration and diabetic retinopathy.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$1,509today

Score Overview

1 Year
Score
Net Growth-13.35%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth0.45%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score1.9
Net Growth-44x
Net TrendNever
Net Income Consistencyโ€”
Rev Growth19.60%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-4x
Net Trend20%
Net Income Consistency
Rev Growth27x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend17%
Net Income Consistency
Rev Growth67x
Rev Trend92%
Revenue Consistency

See the full market ranking โ†’

Ocular Therapeutix Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 17M to $ 51M and net income went from -$ 155M to -$ 265M. Revenue increased in 4 of those 5 years; net income in 0.

Across Ocular Therapeutix Inc's full reported history, from 2014 to 2025, revenue grew from $ 772K to $ 51M and net income went from -$ 28M to -$ 265M. Revenue increased in 92% of the years measured; net income in 17%.

Ocular Therapeutix Inc currently holds a 5-year HDB Score of 1.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 10.23โ€”
1 Year2025-08-12
$ 12.47-18.00%
5 Years2021-08-12
$ 10.90-6.15%
10 Years2016-08-12
$ 6.7850.88%
All Time2014-07-25
$ 13.15-22.21%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 52M-$ 301M$ 598M
2025$ 51M-$ 265M$ 737M
2024$ 63M-$ 193M$ 392M
2023$ 58M-$ 80M$ 195M
2022$ 51M-$ 71M$ 102M
2021$ 43M-$ 6M$ 164M
2020$ 17M-$ 155M$ 228M
2019$ 4M-$ 86M$ 54M
2018$ 1M-$ 57M$ 54M
2017$ 1M-$ 63M$ 41M
2016$ 1M-$ 44M$ 68M
2015$ 1M-$ 39M$ 105M
IPO2014$ 772K-$ 28M$ 74M

Explore beyond OCUL

You're looking at Ocular Therapeutix Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies